Briggs R J, Fabinyi G, Kaye A H
Department of Otolaryngology, The University of Melbourne, Australia.
J Clin Neurosci. 2000 Nov;7(6):521-6. doi: 10.1054/jocn.2000.0728.
The management options for patients with acoustic neuromas is discussed with a review of 164 patients assessed and treated between 1994 and 1998. Twenty-one patients have neurofibromatosis type II. In 33 cases initial observation was undertaken with repeated imaging. Surgical removal of 122 tumours was performed in 121 patients. Eleven of these patients have NF2, of whom three underwent Auditory Brainstem Implantation. Hearing preservation tumour removal was attempted in 37 and was successful in 20 (54%). The middle cranial fossa approach was used in ten cases with 100% successful hearing preservation. The retrosigmoid approach was used in 27 cases with 36% successful hearing preservation. Non-hearing preservation tumour removal was performed in 85 cases where hearing was poor or the tumour measured more than 2 cm within the cerebellopontine angle. The translabyrinthine approach was used in 80 of these patients. Postoperative facial nerve outcome was dependent on tumour size. All 38 patients with tumours </= 1.5 cm have normal (Grade 1) facial function. For all sized tumours, 90% of patients have good facial function (82% Grade 1, 8% Grade 2), 7% of patients have moderate function (6% Grade 3 and 1% Grade 4) and only 3% of patients have poor function (2% Grade 5, 1% Grade 6). Lasting complications were minimal with no operative mortality and eight patients (6.4%) suffering CSF fistulae. Seven patients in this series have had stereotactic radiation with variable outcome. The radiobiology of both single dose and fractionated stereotactic radiation is described and the current role of stereotactic radiation in the management of acoustic neuromas is discussed. Surgical tumour removal by an experienced multi-disciplinary team remains the primary treatment modality for acoustic neuromas. The middle cranial fossa approach is recommended for management of intracanalicular tumours. The translabyrinthine approach facilitates facial nerve preservation, particularly in patients with large tumours.
通过回顾1994年至1998年间评估和治疗的164例患者,讨论了听神经瘤患者的治疗选择。21例患者患有II型神经纤维瘤病。33例患者最初进行观察并重复成像。121例患者接受了122个肿瘤的手术切除。其中11例患者患有NF2,其中3例接受了听觉脑干植入。37例患者尝试进行保留听力的肿瘤切除,20例(54%)成功。10例采用中颅窝入路,听力保留成功率为100%。27例采用乙状窦后入路,听力保留成功率为36%。85例听力较差或肿瘤在桥小脑角内直径超过2 cm的患者进行了不保留听力的肿瘤切除。其中80例患者采用经迷路入路。术后面神经功能结果取决于肿瘤大小。所有38例肿瘤直径≤1.5 cm的患者面神经功能正常(1级)。对于所有大小的肿瘤,90%的患者面神经功能良好(82%为1级,8%为2级),7%的患者面神经功能中等(6%为3级,1%为4级),仅3%的患者面神经功能差(2%为5级,1%为6级)。持久并发症极少,无手术死亡,8例患者(6.4%)出现脑脊液漏。本系列中有7例患者接受了立体定向放射治疗,结果各异。描述了单次剂量和分次立体定向放射治疗的放射生物学,并讨论了立体定向放射治疗在听神经瘤治疗中的当前作用。由经验丰富的多学科团队进行手术肿瘤切除仍然是听神经瘤的主要治疗方式。推荐采用中颅窝入路治疗内耳道肿瘤。经迷路入路有助于保留面神经,特别是对于大肿瘤患者。